Ç÷¾×¾Ï Áø´Ü ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : Á¦Ç°º°, °Ë»çº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
Blood Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product, By Test, By End-use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1654152
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 01¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 150 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
Ç÷¾×¾Ï Áø´Ü ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¼¼°èÀÇ Ç÷¾×¾Ï Áø´Ü ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 160¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç 2025³âºÎÅÍ 2030³â±îÁö 6.87%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.
ÀÌ ½ÃÀåÀº ¹éÇ÷º´, ¸²ÇÁÁ¾, °ñ¼öÁ¾°ú °°Àº Ç÷¾× ¾Ç¼º Á¾¾çÀÇ ¹ßº´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Ç÷¾×¾ÏÀ» Æ÷ÇÔÇÑ ¸¸¼º Áúȯ¿¡ ´õ Ãë¾àÇÑ ³ëÀÎ Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ ½ÃÀåÀº ´õ¿í Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ NGS ¹× ±âŸ ºÐÀÚ Áø´Ü ±â¼úÀ» Æ÷ÇÔÇÑ ±â¼ú ¹ßÀüÀ¸·Î Áø´ÜÀÇ Á¤È®¼º°ú È¿À²¼ºÀÌ Çâ»óµÇ¾î ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» ÁÖµµ ÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
Áö³ 10³â µ¿¾È Ç÷¾×¾Ï Áø´Ü¿¡ ´ëÇÑ Á¢±Ù ¹æ½ÄÀÌ Å©°Ô ¹ßÀüÇßÀ¸¸ç, ÀÌ´Â ¸ðµÎ Áõ°¡ÇÏ´Â Áúº´ÀÇ ¹ß»ý·ü°ú »ç¸Á·üÀ» ÁÙÀ̱â À§ÇÑ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ¾Ï Á¶±â ¹ß°ß·üÀ» ³ôÀÌ´Â µ¥ µµ¿òÀÌ µÇ´Â °ÍÀ¸·Î Àß ¾Ë·ÁÁ® ÀÖÁö¸¸, »ó´çÇÑ ¹ßÀüÀÌ ÀÖ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î, NGS´Â ¾Ï¼¼Æ÷ÀÇ Àüü °Ô³ð ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÏ¿© Á¤È®ÇÑ Áø´Ü°ú ¸ÂÃãÇü Ä¡·á¸¦ ¾È³»ÇÏ´Â À¯ÀüÀû µ¹¿¬º¯ÀÌ¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. 2022³â 10¿ù, ½Ã½º¸ß½º ±×·ìÀÎ OGT´Â È®Àå ÁßÀÎ NGS Á¦Ç°±ºÀ» º¸°Çϱâ À§ÇØ ´Ù¾çÇÑ »õ·Î¿î Á¦Ç°À» Ãâ½ÃÇß½À´Ï´Ù. ƯÈ÷ ´Ù¾çÇÑ °ñ¼ö¼º Áúȯ°ú °ü·ÃµÈ À¯ÀüÀû µ¹¿¬º¯À̸¦ ½Äº°Çϵµ·Ï ¼³°èµÈ SureSeq °ñ¼ö¼º Ç÷¯½º ÆÐ³ÎÀº ÀÌ Áß¿äÇÑ ¿¬±¸ ¿µ¿ª¿¡¼ ȸ»çÀÇ ¿ª·®À» °ÈÇß½À´Ï´Ù.
SPECT/CT, PET ¹× À¯¼¼Æ÷ ºÐ¼®°ú °°Àº ºÐÀÚ À̹Ì¡ ±â¼úÀº ºÐÀÚ À̹Ì¡ ¿¡ÀÌÀüÆ®¸¦ »ç¿ëÇÏ¿© ´Ù¾çÇÑ Áúº´ ´Ü°è¿¡¼ ÁöÇ¥ ºÐÀÚ ¸¶Ä¿¸¦ °¨ÁöÇÏ¿© °¨Áö ¹× ¸ð´ÏÅ͸µÀ» Áö¿øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ À̹Ì¡ ±â¼úÀÇ ¹ßÀüÀ¸·Î Á¤È®µµ¿Í Á¶±â ¹ß°ß ±â´ÉÀÌ Çâ»óµÇ¾î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¼¼°èÀÇ ±â¾÷µéÀº ½ÃÀå Á¡À¯À²À» ³ôÀ̱â À§ÇØ ÀÚµ¿ À̹Ì¡ °Ë»ç¿Í ½Ã½ºÅÛÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 5¿ù, ½Ã½º¸ß½º ÄÚÆÛ·¹À̼ÇÀº ÀϺ»¿¡¼ ÀÓ»ó À¯¼¼Æ÷ ºÐ¼® ½Ã½ºÅÛÀ» Ãâ½ÃÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ½Ã½ºÅÛ¿¡´Â À¯¼¼Æ÷ ºÐ¼®±â XF-1600, ½Ã·á Áغñ ½Ã½ºÅÛ PS-10, Ç×ü ½Ã¾à ¹× ±âŸ °ü·Ã Á¦Ç°ÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ½Ã½ºÅÛÀ» ÅëÇØ ½ÇÇè½ÇÀº ½Ã·á ÁغñºÎÅÍ ÃøÁ¤ °á°ú º¸°í±îÁö À¯¼¼Æ÷ ºÐ¼® °Ë»çÀÇ Àüü ÇÁ·Î¼¼½º¸¦ ÀÚµ¿ÈÇÒ ¼ö ÀÖ¾î È¿À²¼º°ú °Ë»ç Ç¥ÁØÈ¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼¼°èÀÇ °¢±¹ Á¤ºÎ´Â ¹éÇ÷º´ ¹× ¸²ÇÁÁ¾°ú °°Àº Ç÷¾× ¾Ç¼º Á¾¾ç ¹ßº´·ü Áõ°¡·Î ÀÎÇÑ ¸·´ëÇÑ ÀÇ·á ºÎ´ãÀ» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¸¹Àº ±¹°¡¿¡¼ Á¶±â ¹ß°ß°ú °ËÁø ³ë·ÂÀ» ¿ì¼±½ÃÇÏ´Â Æ÷°ýÀûÀÎ ±¹°¡ ¾Ï °ü¸® ÇÁ·Î±×·¥À» ½ÃÀÛÇß½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ¾Ï ¿¬±¸Çùȸ´Â ÃÖ±Ù ¾Ï ¿¬±¸¸¦ °¡¼ÓÈÇÏ°í ¹Ì±¹ ½Ã¹ÎÀÌ ¿¹¹æ °ËÁøÀ» ´õ ½±°í Àú·ÅÇÏ°Ô ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï Çϱâ À§ÇØ Beau Biden Cancer MoonshotÀ» ½ÃÀÛÇß½À´Ï´Ù.
ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Illumina, InVivoScribe, Ipsogen(Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾÷üµéÀº ¼¼°èÀÇ °í°´À» ´ë»óÀ¸·Î Á¦Ç° Ãâ½Ã ¹× ½ÂÀΰú °°Àº ´Ù¾çÇÑ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê¿¡ Âü¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 9¿ù, Adaptive Technologies´Â Ç÷¾×¾ÏÀÇ MRD ¸ð´ÏÅ͸µÀ» À§ÇÑ ºÐÀÚ Áø´Ü °Ë»çÀÎ clonoSEQ¸¦ À§ÇÑ ¿¡ÇÈ ÅëÇÕÀ» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ÅëÇÕÀ» ÅëÇØ ÀÇ·á ¼ºñ½º Á¦°øÀÚ´Â ¿¡ÇÈÀÇ EHR ½Ã½ºÅÛ ³»¿¡¼ Á÷Á¢ clonoSEQ °Ë»ç °á°ú¸¦ ÁÖ¹®ÇÏ°í °ËÅäÇÒ ¼ö ÀÖ¾î ÀÓ»ó ÀÇ»ç °áÁ¤À» °£¼ÒÈÇϰí ȯÀÚ Ä¡·á¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.
Ç÷¾×¾Ï Áø´Ü ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- Á¦Ç°º°·Î´Â 2024³â Ç÷¾×¾Ï Áø´Ü ½ÃÀå¿¡¼ ºÐ¼® ŰƮ¿Í ½Ã¾àÀÌ °¡Àå Å« ¸ÅÃâ ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ³ôÀº Á¡À¯À²Àº ºÐ¼® ŰƮ ¹× ½Ã¾àÀÌ Æ¯Á¤ ¹ÙÀÌ¿À ¸¶Ä¿, À¯ÀüÀÚ µ¹¿¬º¯ÀÌ ¹× ±âŸ ÁöÇ¥¸¦ °¨ÁöÇϵµ·Ï ¼³°èµÇ¾î ÀÇ·á Àü¹®°¡°¡ Áúº´À»º¸´Ù È¿°úÀûÀ¸·Î Áø´ÜÇϰí Ä¡·áÇÒ ¼ö ÀÖµµ·ÏÇϱ⠶§¹®ÀÔ´Ï´Ù.
- °Ë»çº°·Î, Ç÷¾× °Ë»ç ºÎ¹®ÀÌ ½ÃÀåÀ» Àå¾ÇÇϰí 2024³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â Ç÷¾×¾Ï °ËÃâÀ» À§ÇÑ Ç÷¾× °Ë»ç ŰƮÀÇ Çõ½Å°ú °¡¿ë¼º Áõ°¡¿¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù.
- ÃÖÁ¾ ¿ëµµ¿¡ µû¶ó º´¿ø ¹× Ŭ¸®´ÐÀº 2024³â Ç÷¾×¾Ï Áø´Ü ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Áö¹èÇß½À´Ï´Ù. ÀÌ´Â Áúº´ Áø´Ü, Ç÷±¸ ¼ö, Ç÷¾×Çü °Ë»ç¸¦ À§ÇÑ ¹ýÀÇÇÐ ½ÇÇè½Ç°ú º´¿ø ÀÇ·á ½ÇÇè½ÇÀÇ ¼ö¿ä Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ º´¿ø ½ÇÇè½ÇÀÇ °³¹ßÀº ȯÀÚÀÇ ÁøÈÇÏ´Â ¿ä±¸¸¦ ÇØ°áÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, ´õ ¸¹Àº º´¿ø¿¡¼ ´Ù¾çÇÑ ¼ºñ½º¸¦ Á¦°øÇÏ´Â °ÍÀ» ¸ñÇ¥·ÎÇÕ´Ï´Ù.
- ºÏ¹Ì´Â ¸¹Àº ÁÖ¿ä ½ÃÀå ¾÷üÀÇ Á¸Àç·Î ÀÎÇØ ½ÃÀåÀ» Áö¹èÇßÀ¸¸ç, ºÏ¹Ì´Â ¹éÇ÷º´°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ ³ô½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´Àº Á¤±âÀû ÀÎ ¸ð´ÏÅ͸µ ¹× Áø´Ü °Ë»ç°¡ ÇÊ¿äÇϹǷΠ°í±Þ ´ç´¢º´¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù.
- ¾Æ½Ã¾ÆÅÂÆò¾çÀº 2025³âºÎÅÍ 2030³â±îÁö ¿¹Ãø ±â°£ µ¿¾È Çõ½ÅÀûÀÎ ÀåÄ¡ Á¦Á¶ ´É·Â°ú °¡¼ÓÈ µÈ Áø´Ü ¿¬±¸ ´É·ÂÀ» °®Ãá Á¦Á¶¾÷üÀÇ Á¸Àç·Î ÀÎÇØ °¡Àå ºü¸¥ ¼ºÀåÀ» ¸ñ°Ý ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Ç÷¾×¾Ï Áø´Ü ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅëÀÇ Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã ¹× º¸Á¶ÀûÀÎ ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- Ç÷¾×¾Ï Áø´Ü ½ÃÀå ºÐ¼® Åø
- »ê¾÷ ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå Ç÷¾×¾Ï Áø´Ü ½ÃÀå : Á¦Ç°º°, ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- Ç÷¾×¾Ï Áø´Ü ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®(2018-2030³â)
- ±â±â
- ºÐ¼® ŰƮ ¹× ½Ã¾à
Á¦5Àå Ç÷¾×¾Ï Áø´Ü ½ÃÀå : °Ë»çº°, ÃßÁ¤ ¹× µ¿Ç⠺м®
- °Ë»ç ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
- ºÎ¹® ´ë½Ãº¸µå
- °Ë»ç¿¡ ÀÇÇÑ ¼¼°èÀÇ Ç÷¾×¾Ï Áø´Ü ½ÃÀå Àü¸Á
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®(2018-2030³â)
- Ç÷¾×°Ë»ç
- È»ó °Ë»ç
- »ý°Ë
- ºÐÀÚ Áø´Ü °Ë»ç
Á¦6Àå Ç÷¾×¾Ï Áø´Ü ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤ ¹× µ¿Ç⠺м®
- ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
- ºÎ¹® ´ë½Ãº¸µå
- ÃÖÁ¾ ¿ëµµ¿¡ ÀÇÇÑ ¼¼°èÀÇ Ç÷¾×¾Ï Áø´Ü ½ÃÀå Àü¸Á
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®(2018-2030³â)
- º´¿ø ¹× Ŭ¸®´Ð
- Áø´Ü ½ÇÇè½Ç
- ¿¬±¸±â°ü
Á¦7Àå Ç÷¾×¾Ï Áø´Ü ½ÃÀå : Áö¿ªº°, ÃßÁ¤ ¹× µ¿Ç⠺м®
- Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â, 2030³â)
- Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
- ¼¼°èÀÇ Áö¿ª ½ÃÀå ÇöȲ
- ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®(2018-2030³â)
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ³ë¸£¿þÀÌ
- ½º¿þµ§
- µ§¸¶Å©
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- Çѱ¹
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦8Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
- ±â¾÷ ¹× °æÀïÀÇ ºÐ·ù
- º¥´õ »óȲ
- ÁÖ¿ä ¸®¼¿·¯¿Í ä³Î ÆÄÆ®³Ê ¸ñ·Ï
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
- Illumina
- InVivoScribe
- Ipsogen(Qiagen)
- Asuragen(Bio-Techne)
- Danaher Corporation
- Abbott
- Sequenta(Adaptive bIoTechnologies)
- SkylineDx
- Bio-Rad Laboratories
- Alercell
- Sophia Genetics
HBR
¿µ¹® ¸ñÂ÷
Blood Cancer Diagnostics Market Growth & Trends:
The global blood cancer diagnostics market size is expected to reach USD 16.04 billion by 2030, registering a CAGR of 6.87% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of blood malignancies, such as leukemia, lymphoma, and myeloma. The market is further expected to grow significantly due to the increasing elderly population, which is more susceptible to chronic diseases, including blood cancer. In addition, technological advancements, including NGS and other molecular diagnostic techniques, are improving the accuracy & efficiency of diagnosis, which is likely to drive the market over the forecast period.
Over the past decade, significant advancements have been made in approaches to blood cancer diagnostics, all aimed at reducing the growing incidence of diseases and their mortality. While these advancements have been well-documented to increase early cancer detection, there have been considerable advancements. For instance, NGS has enabled the analysis of the entire genome of cancer cells, providing insights into genetic mutations that guide precise diagnosis and tailored treatments. In October 2022, OGT, a Sysmex group, introduced a range of new offerings to augment its expanding NGS product suite. Notably, the SureSeq Myeloid Plus panel was designed to identify genetic mutations associated with various Myeloid disorders, enhancing the company's capabilities in this critical area of research.
Molecular imaging techniques, such as SPECT/CT, PET, and flow cytometry, utilize molecular imaging agents to detect indicative molecular markers at different disease stages, aiding detection & monitoring. Such advancements in imaging technologies offer improved accuracy and early detection capabilities, driving the market. The global players are introducing automatic imaging tests and systems to boost their market share. For instance, in May 2023, Sysmex Corporation announced the launch of the Clinical Flow Cytometry System in Japan. The system includes Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products. This system enables laboratories to automate the entire process of flow cytometry testing, from sample preparation to the reporting of measurement results, contributing to higher efficiency & testing standardization.
Governments across the world have recognized the immense healthcare burden posed by rising incidences, including hematological malignancies such as leukemia & lymphoma. In response, many countries have launched comprehensive national cancer control programs that prioritize early detection and screening efforts. For instance, the American Association of Cancer Research recently launched the Beau Biden Cancer Moonshot initiative to accelerate cancer research and make preventive screening more accessible & affordable for U.S. citizens.
Some of the key players in the market are Illumina, InVivoScribe, Ipsogen (Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories and others. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in September 2023, Adaptive Technologies launched Epic integration for clonoSEQ, a molecular diagnostic test for MRD monitoring in blood cancers. This integration allows healthcare providers to order and review clonoSEQ test results directly within Epic's EHR system, streamlining clinical decision-making and improving patient care.
Blood Cancer Diagnostics Market Report Highlights:
- Based on product, the assay kits and reagents accounted for the largest revenue share of the blood cancer diagnostics market in 2024. This high share is attributable to assay kits & reagents being designed to detect specific biomarkers, genetic mutations, and other indicators, enabling healthcare professionals to diagnose & treat the disease more effectively
- Based on tests, blood tests segment dominated the market and accounted for the largest share in 2024. This can be attributed to increasing innovation and availability of blood test kits for blood cancer detection
- Based on end use, hospitals and clinics dominated the market with the largest share of blood cancer diagnostics market in 2024. This is attributable to growing demand in forensic labs and hospital medical labs for disease diagnosis, blood cell counts, blood typing. Furthermore, Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals aim to provide a wide range of services in their settings
- North America dominated the market due to the presence of a large number of major market players, North America has a high prevalence of chronic diseases like leukemia These diseases require regular monitoring and diagnostic testing, fueling the demand for advanced diagnostic tools and technologies
- Asia Pacific is expected to witness the fastest growth over the forecast period from 2025 to 2030, due to the presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Test
- 1.2.3. End Use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline.
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Test outlook
- 2.2.3. End Use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Blood Cancer Diagnostics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing prevalence of blood cancer
- 3.2.1.2. Increasing R&D and clinical trials
- 3.2.1.3. Advancements in diagnostics technologies
- 3.2.1.4. Rising government initiatives and regulatory support
- 3.2.2. Market restraint analysis
- 3.2.2.1. High development cost and accessibility barriers
- 3.3. Blood Cancer Diagnostics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
Chapter 4. Blood Cancer Diagnostics Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Blood Cancer Diagnostics Market: Product Movement Analysis
- 4.3. Blood Cancer Diagnostics Market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
- 4.4. Instruments
- 4.4.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Assay Kits and Reagents
- 4.5.1. Assay Kits and Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Blood Cancer Diagnostics Market: Test Estimates & Trend Analysis
- 5.1. Test Market Share, 2024 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Blood Cancer Diagnostics Market by Test Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5. Blood Tests
- 5.5.1. Blood Tests Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Imaging Tests
- 5.6.1. Imaging Tests Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Biopsy
- 5.7.1. Biopsy Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.8. Molecular Test
- 5.8.1. Molecular Tests Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Blood Cancer Diagnostics Market: End-use Estimates & Trend Analysis
- 6.1. End Use Market Share, 2024 & 2030
- 6.2. Segment Dashboard
- 6.3. Global Blood Cancer Diagnostics Market by End Use Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5. Hospitals and Clinics
- 6.5.1. Hospitals and Clinics Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Diagnostic Labs
- 6.6.1. Diagnostic Labs Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. Research Institutes
- 6.7.1. Research Institutes Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Blood Cancer Diagnostics Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.5. North America
- 7.5.1. U.S.
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/Reimbursement
- 7.5.1.3. Competitive scenario
- 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. Canada
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/Reimbursement
- 7.5.2.3. Competitive scenario
- 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. Mexico
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework/Reimbursement
- 7.5.3.3. Competitive scenario
- 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Europe
- 7.6.1. UK
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework/Reimbursement
- 7.6.1.3. Competitive scenario
- 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. Germany
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework/Reimbursement
- 7.6.2.3. Competitive scenario
- 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.3. France
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Regulatory framework/Reimbursement
- 7.6.3.3. Competitive scenario
- 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.4. Italy
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Regulatory framework/Reimbursement
- 7.6.4.3. Competitive scenario
- 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.5. Spain
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Regulatory framework/Reimbursement
- 7.6.5.3. Competitive scenario
- 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.6. Norway
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Regulatory framework/Reimbursement
- 7.6.6.3. Competitive scenario
- 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.7. Sweden
- 7.6.7.1. Key country dynamics
- 7.6.7.2. Regulatory framework/Reimbursement
- 7.6.7.3. Competitive scenario
- 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.8. Denmark
- 7.6.8.1. Key country dynamics
- 7.6.8.2. Regulatory framework/Reimbursement
- 7.6.8.3. Competitive scenario
- 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7. Asia Pacific
- 7.7.1. Japan
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework/Reimbursement
- 7.7.1.3. Competitive scenario
- 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. China
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework/Reimbursement
- 7.7.2.3. Competitive scenario
- 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.3. India
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework/Reimbursement
- 7.7.3.3. Competitive scenario
- 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.4. Australia
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Regulatory framework/Reimbursement
- 7.7.4.3. Competitive scenario
- 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.5. South Korea
- 7.7.5.1. Key country dynamics
- 7.7.5.2. Regulatory framework/Reimbursement
- 7.7.5.3. Competitive scenario
- 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.6. Thailand
- 7.7.6.1. Key country dynamics
- 7.7.6.2. Regulatory framework/Reimbursement
- 7.7.6.3. Competitive scenario
- 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8. Latin America
- 7.8.1. Brazil
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Regulatory framework/Reimbursement
- 7.8.1.3. Competitive scenario
- 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.2. Argentina
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Regulatory framework/Reimbursement
- 7.8.2.3. Competitive scenario
- 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 7.9. MEA
- 7.9.1. South Africa
- 7.9.1.1. Key country dynamics
- 7.9.1.2. Regulatory framework/Reimbursement
- 7.9.1.3. Competitive scenario
- 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.9.2. Saudi Arabia
- 7.9.2.1. Key country dynamics
- 7.9.2.2. Regulatory framework/Reimbursement
- 7.9.2.3. Competitive scenario
- 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.9.3. UAE
- 7.9.3.1. Key country dynamics
- 7.9.3.2. Regulatory framework/Reimbursement
- 7.9.3.3. Competitive scenario
- 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.9.4. Kuwait
- 7.9.4.1. Key country dynamics
- 7.9.4.2. Regulatory framework
- 7.9.4.3. Competitive scenario
- 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2024
- 8.3.4. Illumina
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Services benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. InVivoScribe
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Services benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Ipsogen (Qiagen)
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Services benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Asuragen(Bio-Techne)
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Services benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Danaher Corporation
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Services benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Abbott
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Services benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. Sequenta (Adaptive biotechnologies)
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Services benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. SkylineDx
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Services benchmarking
- 8.3.11.4. Strategic initiatives
- 8.3.12. Bio-Rad Laboratories
- 8.3.12.1. Company overview
- 8.3.12.2. Financial performance
- 8.3.12.3. Services benchmarking
- 8.3.12.4. Strategic initiatives
- 8.3.13. Alercell
- 8.3.13.1. Company overview
- 8.3.13.2. Financial performance
- 8.3.13.3. Services benchmarking
- 8.3.13.4. Strategic initiatives
- 8.3.14. Sophia Genetics
- 8.3.14.1. Company overview
- 8.3.14.2. Financial performance
- 8.3.14.3. Services benchmarking
- 8.3.14.4. Strategic initiatives
°ü·ÃÀÚ·á